中枢神经系统疾病治疗方法开发商MapLight Therapeutics宣布完成3.725亿美元D轮融资-动脉网

MapLight Therapeutics Announces $372.5 Million Series D Financing

CISION 等信源发布 2025-07-28 19:59



可切换为仅中文







REDWOOD CITY, Calif.

加利福尼亚州红木城

，

July 28, 2025

2025年7月28日

/PRNewswire/ -- MapLight Therapeutics today announced an oversubscribed

/PRNewswire/ -- MapLight Therapeutics今天宣布超额认购

$372.5 million

3.725亿美元

Series D financing. The financing was co-led by Forbion and Life Sciences at Goldman Sachs Alternatives, with participation from additional new investors, including Sanofi, accounts advised by T. Rowe Price Investment Management, Inc. and Avego BioScience Capital. The financing also included strong participation from MapLight's existing investors, including funds managed by Novo Holdings, .

D轮融资。本轮融资由Forbion和高盛资产管理公司（Goldman Sachs Alternatives）的生命科学部门共同领投，其他新投资者也参与其中，包括赛诺菲（Sanofi）、T. Rowe Price投资管理公司建议的账户以及Avego BioScience Capital。现有投资者也积极参与了本轮融资，包括由Novo Holdings管理的基金。

5AM

早上5点

Ventures, Blue Owl Healthcare Opportunities and others.

风险投资公司、蓝猫头鹰医疗机会等。

MapLight's lead program, ML-007C-MA, is an oral fixed-dose combination of the investigational M

MapLight的主导项目ML-007C-MA是一种口服固定剂量组合，包含在研的M

muscarinic agonist, ML-007, co-formulated with a peripherally acting anticholinergic (PAC). ML-007C-MA is designed to activate both M

毒蕈碱激动剂 ML-007 与外周作用抗胆碱能药物 (PAC) 联合使用。ML-007C-MA 旨在激活 M

and M

和 M

muscarinic receptors in the CNS to drive efficacy, while synchronizing the pharmacokinetics of the agonist and antagonist components to mitigate peripheral cholinergic side effects.

中枢神经系统中的毒蕈碱受体以提高疗效，同时同步激动剂和拮抗剂成分的药代动力学，以减轻外周胆碱能副作用。

With this financing, MapLight will advance ML-007C-MA through ongoing Phase 2 trials for schizophrenia and Alzheimer's disease psychosis. The financing will also fund the exploration of other potential indications for ML-007C-MA, as well as the continued advancement of other clinical and preclinical pipeline programs..

通过此次融资，MapLight 将推动 ML-007C-MA 在精神分裂症和阿尔茨海默病精神病的第二阶段试验中的进展。这笔资金还将用于探索 ML-007C-MA 的其他潜在适应症，以及持续推进其他临床和临床前管线项目。

'The caliber of this new investor group, combined with the continued strong support from our high-quality existing shareholders, is a testament to MapLight's compelling vision and strategy,' said

“这家新投资集团的水平，加上我们现有的高质量股东一如既往的大力支持，证明了MapLight的愿景和战略非常有吸引力，”

Christopher Kroeger

克里斯托弗·克罗格

, M.D., M.B.A., Chief Executive Officer and Founder of MapLight. 'This financing is a clear validation of our differentiated product pipeline, dedicated team and commitment to advancing new medicines for brain disorders that make a difference in the lives of patients and their families.'

，医学博士，工商管理硕士，MapLight的首席执行官兼创始人。“此次融资明确验证了我们差异化的产品线、专注的团队以及为脑部疾病推进新药研发的决心，这些努力将为患者及其家庭的生活带来改变。”

In connection with the financing, Nanna Lüneborg, Ph.D., M.B.A., General Partner at Forbion will join the Board of Directors of MapLight. 'We see significant opportunity in ML-007C-MA as a potential best-in-class M

与此融资相关，Forbion的普通合伙人Nanna Lüneborg博士、工商管理硕士将加入MapLight董事会。 “我们看到ML-007C-MA作为潜在的同类最佳M产品的重要机会。

muscarinic agonist that is well positioned to address the substantial unmet medical need in schizophrenia, ADP and other CNS indications,' said Nanna Lüneborg.

“这是一种毒蕈碱激动剂，非常适合解决精神分裂症、ADP 和其他中枢神经系统适应症中大量未满足的医疗需求，”Nanna Lüneborg 说。

'We are excited to partner with the outstanding team and investor syndicate at MapLight to fuel these important new innovations in the CNS space,' said

“我们很高兴与MapLight的优秀团队和投资者集团合作，推动CNS领域这些重要的新创新，”

Josh Richardson

约什·理查德森

, M.D., Managing Director, Life Sciences at Goldman Sachs Alternatives.

，医学博士，高盛另类投资公司生命科学董事总经理。

Learn more at

了解更多请访问

www.maplightrx.com

。

For investor inquiries:

投资者咨询：

investors@maplightrx.com

投资者@马普莱特RX.com

For media inquiries:

媒体查询：

media@maplightrx.com

About MapLight

关于MapLight

MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients.

MapLight Therapeutics 是一家临床阶段的生物制药公司，致力于改善中枢神经系统疾病患者的生活。该公司由全球公认的精神病学和神经科学研究领域的领导者创立，旨在解决目前缺乏针对特定神经回路的药物治疗的问题。

MapLight's discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation..

MapLight的发现平台具有填补这一空白的潜力，它可以识别与疾病有因果关系的神经回路，并将这些回路作为治疗调节的目标。

About Forbion

关于Forbion

Forbion is a leading global venture capital firm with deep expertise in

Forbion是一家全球领先的风险投资公司，拥有深厚的专业知识在

Europe

欧洲

and offices in Naarden,

并在纳尔登设有办事处，

The Netherlands

荷兰

，

Munich, Germany

德国慕尼黑

and

和

Boston

波士顿

，

USA

美国

. Forbion invests in innovative biotech companies, managing approximately €5 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. In addition, Forbion leverages its biotech expertise beyond human health to address 'planetary health' challenges through its BioEconomy fund strategy, which invests in companies developing sustainable solutions in food, agriculture, materials, and environmental technologies.

Forbion投资于创新型生物技术公司，管理着大约50亿欧元的多个基金策略，涵盖（生物）制药开发的所有阶段。此外，Forbion还通过其生物经济基金策略，将其生物技术专业知识应用于人类健康之外，以应对“地球健康”挑战，该策略投资于在食品、农业、材料和环境技术领域开发可持续解决方案的公司。

Forbion's team consists of over 30 investment professionals that have built an impressive performance track record since the late nineties with 130 investments across 11 funds. Forbion's record of sourcing, building and guiding life sciences companies has resulted in many approved breakthrough therapies and valuable exits.

Forbion的团队由30多名投资专业人士组成，自上世纪90年代末以来，通过11只基金进行了130项投资，建立了令人印象深刻的投资业绩记录。Forbion在生命科学公司方面的挖掘、建设和指导记录已带来了许多获批的突破性疗法和高价值退出成果。

Forbion typically selects impactful investments that will positively affect the health and well-being of people and the planet, as well as meet its financial return objectives. The firm is a signatory to the United Nations Principles for Responsible Investment. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and .

Forbion通常会选择那些能够对人类和地球的健康与福祉产生积极影响，并且符合其财务回报目标的投资。该公司是联合国负责任投资原则的签署方。Forbion与BGV（种子和早期基金的管理者）运营着一家合资企业，特别专注于比荷卢地区。

Germany

德国

。

About Life Sciences at Goldman Sachs Alternatives

高盛另类投资中的生命科学相关业务

Goldman Sachs is one of the leading investors in alternatives globally, with over

高盛是全球领先的另类投资机构之一，拥有超过

$500 billion

5000亿美元

in assets and more than 30 years of experience. The business invests in the full spectrum of alternatives including private equity, growth equity, private credit, real estate, infrastructure, sustainability, and hedge funds. Clients access these solutions through direct strategies, customized partnerships, and open-architecture programs..

在资产和超过30年的经验方面。该业务投资于全方位的替代品，包括私募股权、成长型股权、私人信贷、房地产、基础设施、可持续性和对冲基金。客户通过直接策略、定制合作伙伴关系和开放式架构项目来获取这些解决方案。

The business is driven by a focus on partnership and shared success with its clients, seeking to deliver long-term investment performance drawing on its global network and deep expertise across industries and markets.

该企业注重与客户建立合作关系，追求共同成功，致力于利用其全球网络以及在各行业和市场的深厚专业知识，提供长期的投资回报。

Life Sciences at Goldman Sachs Alternatives was established in 2021 and focuses on later-stage venture investments, targeting therapeutic companies in early clinical development with multi-asset portfolios. The Life Sciences team bring decades of experience investing in the sector and leverage the expansive resources of the Goldman Sachs platform to source differentiated investments and partner with companies to enhance value creation..

高盛另类投资公司（Goldman Sachs Alternatives）的生命科学部门成立于2021年，专注于后期风险投资，目标是拥有多种资产组合的、处于早期临床开发阶段的治疗公司。生命科学团队在该领域拥有数十年的投资经验，并利用高盛平台的广泛资源寻找差异化投资机会，与各公司合作以提升价值创造。

The alternative investments platform is part of Goldman Sachs Asset Management, which delivers investment and advisory services across public and private markets for the world's leading institutions, financial advisors and individuals. Goldman Sachs has approximately

另类投资平台是高盛资产管理公司的一部分，该公司为全球领先的机构、财务顾问和个人提供公共和私人市场的投资和咨询服务。高盛大约有

$3.3 trillion

3.3万亿美元

in assets under supervision globally as of

截至全球监管下的资产

June 30, 2025

2025年6月30日

。

SOURCE MapLight Therapeutics, Inc.

来源：MapLight Therapeutics, Inc.

WANT YOUR COMPANY'S NEWS

想要你公司的新闻吗？